Baseline characteristics of all treated patients (N = 33)
| Characteristic . | n or n/N (%) . |
|---|---|
| Age, y | |
| Median | 64 |
| Range | 50-82 |
| Male sex | 20 (61) |
| ECOG performance status ≤1 | 32 (97) |
| Rai stage III-IV | 9 (27) |
| Bulky disease ≥5 cm | 10/32 (31) |
| β2-microglobulin >3 mg/L | 21/27 (78) |
| No. of prior therapies | |
| Median | 4 |
| Range | 2-13 |
| Ibrutinib as most recent prior therapy* | 30 (91) |
| Duration of prior ibrutinib treatment, mo | |
| Median | 12 |
| Range | 1-62 |
| Time from ibrutinib end to acalabrutinib start, d | |
| Median | 47 |
| Range | 3-331 |
| Baseline cytopenias | |
| ANC ≤1.5 × 109/L | 4 (12) |
| Hemoglobin ≤11.0 g/dL | 9 (27) |
| Platelets ≤100 × 109/L | 13 (39) |
| Genomic status | |
| del(11q) | 7/32 (22) |
| del(17p) | 12/32 (38) |
| del(13q) | 21/27 (78) |
| TP53 mutation | 8/27 (30) |
| NOTCH1 mutation | 2/27 (7) |
| SF3B1 mutation | 4/27 (15) |
| Unmutated IGHV | 25/31 (81) |
| Characteristic . | n or n/N (%) . |
|---|---|
| Age, y | |
| Median | 64 |
| Range | 50-82 |
| Male sex | 20 (61) |
| ECOG performance status ≤1 | 32 (97) |
| Rai stage III-IV | 9 (27) |
| Bulky disease ≥5 cm | 10/32 (31) |
| β2-microglobulin >3 mg/L | 21/27 (78) |
| No. of prior therapies | |
| Median | 4 |
| Range | 2-13 |
| Ibrutinib as most recent prior therapy* | 30 (91) |
| Duration of prior ibrutinib treatment, mo | |
| Median | 12 |
| Range | 1-62 |
| Time from ibrutinib end to acalabrutinib start, d | |
| Median | 47 |
| Range | 3-331 |
| Baseline cytopenias | |
| ANC ≤1.5 × 109/L | 4 (12) |
| Hemoglobin ≤11.0 g/dL | 9 (27) |
| Platelets ≤100 × 109/L | 13 (39) |
| Genomic status | |
| del(11q) | 7/32 (22) |
| del(17p) | 12/32 (38) |
| del(13q) | 21/27 (78) |
| TP53 mutation | 8/27 (30) |
| NOTCH1 mutation | 2/27 (7) |
| SF3B1 mutation | 4/27 (15) |
| Unmutated IGHV | 25/31 (81) |
ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group.
Other most recent prior therapies: venetoclax, n = 1; methylprednisolone with rituximab, n = 1; investigational drug (TG02), n = 1.